Oncolytics names Kennealey as SVP and CMOOncolytics names Kennealey as SVP and CMO
Oncolytics Biotech Inc (C:ONC)
Shares Issued 71,239,918
Last Close11/9/2011 $4.68
Thursday November 10 2011 - News Release
Dr. Brad Thompson reports
ONCOLYTICS BIOTECH ANNOUNCES APPOINTMENTS TO SENIOR MANAGEMENTTEAM
Oncolytics Biotech Inc. has appointed Dr. Gerard Kennealey,MD, as senior vice-president of clinical development and chief medical officer.George M. Gill, MD, Oncolytics' CMO since July 2011, will return to his previousrole as Senior Vice President of Regulatory Affairs and also has been appointedChief Safety Officer.
"Dr. Kennealey is an excellent addition to our clinicaldevelopment team bringing extensive experience with new oncology drugsubmissions, regulatory reviews and clinical trial management to his new role,"said Dr. Brad Thompson, President and CEO of Oncolytics. "Dr. Kennealey and Dr.Gill form a strong team that will advance our proprietary product,REOLYSINAtrademark, through late-stage clinical testing and global regulatoryapprovals."
Dr. Kennealey holds a B.S. (Biology) from Boston College andan MD from the Yale University School of Medicine. Following his medicaltraining and a decade as a practicing oncologist, Dr. Kennealey worked forAstraZeneca where he held positions including Vice President, US MedicalAffairs; Vice President, Oncology Clinical Research; and Global Product Directorfor FaslodexAtrademark. Dr. Kennealey subsequently held an array ofprogressively senior positions with other companies in the life sciencesindustry, as Senior Vice President & Chief Medical Officer at EximiasPharmaceuticals; Senior Vice President, Drug Development at MGI Pharma; and VicePresident of Business Development at Cephalon Inc. Most recently, Dr. Kennealeywas Vice President of Scientific Affairs at Cephalon Inc.
Dr. Gill holds a B.Sc. (Chemistry) from Dickinson College andan MD from the School of Medicine of the University of Pennsylvania, and isboard certified in pediatrics. He began his career in the pharmaceuticalindustry at Hoffman-La Roche, where he held a variety of positions, including asDirector of the Clinical Oncology Group and Associate Director of RegulatoryAffairs. He was subsequently Vice President of Clinical Research and VicePresident of Medical Affairs at Ligand Pharmaceuticals; Senior Director and Headof U.S. Clinical and Medical Affairs for ICI Pharmaceuticals (now AstraZeneca);and Vice President and Head of Worldwide Regulatory Affairs for theBristol-Myers Company (now Bristol-Meyers Squibb). Dr. Gill joined Oncolytics in2002.
We seek Safe Harbor.
© 2011 Canjex Publishing Ltd.